MedTrace Logo

Perinatal Thoraco-abdomino-pelvic Tumors Study

NCT06365268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2025-09-19

No results posted yet for this study

Summary

Congenital tumors are a rare diagnosis in the fetus and newborn. They differ from those of children and adults in terms of the nature, location and evolution of the tumor.

Indeed, some histologically benign tumors may have lethal potential in utero (e.g. sacrococcygeal teratomas) or even undergo malignant transformation if left untreated. In contrast, other tumors that are malignant by histological criteria may have a very good prognosis, regressing spontaneously within the first year of life (e.g. neuroblastoma).

Despite advances in imaging, benign and malignant solid tumors remain a major diagnostic and prognostic challenge in the antenatal context.

The management of congenital tumors requires multidisciplinary expertise, taking into account the perinatal context, which poses specific problems, particularly in terms of therapeutic aspects, but also the frequent existence of associated malformations and/or genetic predisposition syndromes.

This study focuses on solid tumors of the thoraco-abdomino-pelvic region, the main objective being to investigate the correlation between antenatal clinical and radiological analysis and confirmed postnatal diagnosis of congenital solid truncal tumors, as well as the developmental spectrum in which they fit.

Conditions

  • Perinatal Solid Tumors of the Thoraco-abdomino-pelvic Region

Interventions

OTHER

Collection of data from the patient's medical file

Collection of data from the patient's medical file. The data collected concerns a period of three years maximum.

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Sabine SARNACKI, M.D., PhD · Assistance Publique - Hôpitaux de Paris

  • Chelsea KHAWAND, M.D. · Assistance Publique - Hôpitaux de Paris

Eligibility

Max Age
3 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-05
Primary Completion
2024-10-10
Completion
2024-10-10

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06365268 on ClinicalTrials.gov